Dr Lal Pathlabs Ltd

Dr Lal Pathlabs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dr Lal Pathlabs Ltd

₹ 1,698 3.16%
19 May 4:01 p.m.
lalpathlabs.com BSE: 539524 NSE: LALPATHLAB
About

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]

Key Points

Largest Diagnostic Chain
It is the largest diagnostics chain with a Pan-India presence. The company has 75 years of experience in the field of diagnostics and has served 131 million patients in the last five years. Its test offerings range from basic preventive health packages like SwasthFit to the most advanced investigations, including Comprehensive Genomic Profiles, Myeloid testing for Hematological Malignancies, and Amyloid Typing Solutions. [1] [2]

Website BSE NSE
  • Market Cap ₹ 28,473 Cr.
  • Current Price ₹ 1,698
  • High / Low ₹ 1,771 / 1,272
  • Stock P/E 53.6
  • Book Value ₹ 148
  • Dividend Yield 0.83 %
  • ROCE 29.4 %
  • ROE 23.1 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 54.8%

Cons

  • Stock is trading at 11.5 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Smallcap 100 BSE SmallCap Select Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
431 480 532 476 521 574 631 569 577 641 700 632 675
315 344 369 346 383 413 437 418 418 457 484 458 494
Operating Profit 116 136 163 130 138 161 194 151 159 183 215 174 182
OPM % 27% 28% 31% 27% 26% 28% 31% 27% 28% 29% 31% 27% 27%
12 15 14 15 16 31 24 31 25 26 23 -4 37
Interest 8 7 7 6 6 6 6 5 5 4 5 7 6
Depreciation 21 18 19 19 35 33 33 34 35 33 38 40 43
Profit before tax 98 125 151 120 113 154 179 144 145 172 195 123 170
Tax % 27% 25% 25% 26% 29% 26% 28% 27% -2% 25% 25% 25% 17%
71 94 113 88 81 114 129 105 148 129 146 92 141
EPS in Rs 4.28 5.61 6.77 5.29 4.84 6.86 7.71 6.30 8.88 7.71 8.69 5.50 8.42
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
637 765 882 1,024 1,165 1,274 1,491 1,879 1,769 2,125 2,352 2,648
486 562 651 768 882 946 1,083 1,366 1,308 1,544 1,684 1,894
Operating Profit 151 204 230 256 283 328 408 512 461 581 668 754
OPM % 24% 27% 26% 25% 24% 26% 27% 27% 26% 27% 28% 28%
17 20 28 31 46 58 51 53 47 66 109 83
Interest 0 0 1 1 1 15 15 29 34 29 22 22
Depreciation 32 32 26 31 36 68 70 76 82 136 134 154
Profit before tax 135 192 231 256 292 303 374 461 391 483 621 660
Tax % 32% 34% 34% 34% 33% 26% 25% 25% 25% 28% 20% 23%
92 126 152 168 195 223 280 345 292 347 497 508
EPS in Rs 8.40 7.60 9.18 10.09 11.72 13.39 16.80 20.71 17.54 20.76 29.74 30.33
Dividend Payout % 9% 16% 16% 22% 26% 45% 60% 29% 34% 43% 40% 81%
Compounded Sales Growth
10 Years: 13%
5 Years: 12%
3 Years: 14%
TTM: 13%
Compounded Profit Growth
10 Years: 16%
5 Years: 14%
3 Years: 22%
TTM: 7%
Stock Price CAGR
10 Years: 13%
5 Years: 3%
3 Years: 19%
1 Year: 18%
Return on Equity
10 Years: 23%
5 Years: 23%
3 Years: 23%
Last Year: 23%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 55 83 83 83 83 83 83 83 83 83 84 168
Reserves 238 397 503 693 847 933 1,134 1,389 1,606 1,717 2,051 2,305
27 0 0 0 0 0 0 385 281 142 53 193
130 112 90 119 136 302 356 354 350 406 434 383
Total Liabilities 449 592 676 896 1,067 1,318 1,573 2,211 2,320 2,349 2,621 3,049
119 130 121 173 173 297 300 371 361 1,104 1,051 1,144
CWIP 1 4 17 9 3 11 9 14 5 6 3 6
Investments 49 74 134 174 214 253 171 1,062 1,213 213 416 513
280 384 404 540 677 757 1,093 764 740 1,026 1,151 1,386
Total Assets 449 592 676 896 1,067 1,318 1,573 2,211 2,320 2,349 2,621 3,049

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
94 142 167 189 208 272 373 426 428 478 540 606
-86 -148 -134 -166 -93 -19 -195 -449 -288 32 -293 -382
1 1 -32 13 -54 -187 -136 141 -270 -404 -325 -256
Net Cash Flow 9 -5 1 36 61 65 42 118 -131 106 -78 -32
Free Cash Flow 63 100 118 123 170 224 338 358 390 429 488 436
CFO/OP 97% 103% 102% 110% 110% 110% 115% 106% 114% 104% 104% 102%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 17 17 17 14 17 14 16 13 13 15 16 18
Inventory Days 37 31 33 44 40 70 38 32 22 28 26 29
Days Payable 89 88 97 104 110 143 132 101 131 154 155 126
Cash Conversion Cycle -35 -41 -47 -45 -54 -59 -79 -55 -96 -111 -113 -79
Working Capital Days -10 28 15 18 1 -16 -25 -57 -61 -46 -28 30
ROCE % 51% 48% 44% 38% 34% 33% 35% 32% 22% 26% 31% 29%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Patients Served (Organic)
Million

Log in to view insights

Please log in to see hidden values.

Login
Realization per Patient
INR

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

12 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
55.01% 54.61% 54.60% 54.60% 54.60% 53.92% 53.91% 53.91% 53.79% 53.21% 53.21% 53.21%
23.27% 24.35% 25.36% 26.15% 25.43% 26.82% 26.82% 23.90% 21.69% 21.86% 20.29% 17.18%
8.34% 8.85% 9.27% 9.40% 12.42% 12.60% 12.88% 15.79% 17.62% 18.22% 19.20% 21.37%
0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.29% 0.27% 0.01% 0.01%
12.65% 11.48% 10.12% 9.24% 6.95% 6.02% 5.82% 5.84% 6.22% 6.07% 6.94% 7.88%
0.44% 0.41% 0.37% 0.32% 0.30% 0.33% 0.28% 0.27% 0.39% 0.37% 0.35% 0.34%
No. of Shareholders 1,74,4441,60,6791,49,9011,46,7411,31,1891,16,6061,16,2361,15,6991,18,6561,12,7031,16,1671,14,527

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls